Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas

PLoS ONE

Volumn 12, Issue 2, 2017, Pages

  Ramachandran, Rahimsan K ^a,b   Sørensen, Mia D ^a,b   Aaberg Jessen, Charlotte ^a,b   Hermansen, Simon K ^a,b   Kristensen, Bjarne W ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; MESSENGER RNA; MONOCLONAL ANTIBODY; TISSUE INHIBITOR OF METALLOPROTEINASE 1; ISOCITRATE DEHYDROGENASE; MMP2 PROTEIN, HUMAN; TIMP1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MMP 2 GENE; OVERALL SURVIVAL; PROTEIN EXPRESSION; TIMP 1 GENE; TUMOR GENE; TUMOR INVASION; BIOLOGY; BRAIN NEOPLASMS; ENZYMOLOGY; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SOFTWARE; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; ASTROCYTOMA; BRAIN NEOPLASMS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SOFTWARE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85014009667     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0172234     Document Type: Article

References (72)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, et al. WHO classification of tumours of the central nervous system, Revised, 4th edition. International Agency for Research on Cancer (IARC), Lyon. 2016.
2. Preusser M, de Ribaupierre S, Wohrer A, Erridge SC, Hegi M, Weller M, et al. Current concepts and management of glioblastoma. Annals of neurology. 2011; 70(1):9-21. Epub 2011/07/26. doi: 10.1002/ ana.22425 PMID: 21786296
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine. 2005; 352 (10):987-96. Epub 2005/03/11. doi: 10.1056/NEJMoa043330 PMID: 15758009
4. Wen PY, Kesari S. Malignant gliomas in adults. The New England journal of medicine. 2008; 359(5):492-507. Epub 2008/08/02. doi: 10.1056/NEJMra0708126 PMID: 18669428
5. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. The lancet oncology. 2012; 13(7):707-15. Epub 2012/05/15. doi: 10.1016/S1470-2045 (12)70164-X PMID: 22578793
6. Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. The lancet oncology. 2012; 13(9):916-26. Epub 2012/08/11. doi: 10.1016/S1470-2045(12)70265-6 PMID: 22877848
7. Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. International journal of cancer Journal international du cancer. 2012; 131(6):1342-50. Epub 2011/12/06. doi: 10.1002/ijc.27385 PMID: 22139906
8. Rempe RG, Hartz AM, Bauer B. Matrix metalloproteinases in the brain and blood-brain barrier: versatile breakers and makers. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism. 2016. Epub 2016/06/22.
9. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. Journal of cell science. 2002; 115(Pt 19):3719-27. Epub 2002/09/18. PMID: 12235282
10. Aaberg-Jessen C, Christensen K, Offenberg H, Bartels A, Dreehsen T, Hansen S, et al. Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival. Journal of neuro-oncology. 2009; 95(1):117-28. Epub 2009/05/12. doi: 10.1007/s11060-009-9910-8 PMID: 19430729
11. Crocker M, Ashley S, Giddings I, Petrik V, Hardcastle A, Aherne W, et al. Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor. Neuro-oncology. 2011; 13(1):99-108. Epub 2010/12/18. doi: 10.1093/neuonc/noq170 PMID: 21163810
12. Nuttall RK, Pennington CJ, Taplin J, Wheal A, Yong VW, Forsyth PA, et al. Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Molecular cancer research: MCR. 2003; 1(5):333-45. Epub 2003/03/26. PMID: 12651907
13. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature reviews Cancer. 2002; 2(3):161-74. Epub 2002/05/07. doi: 10.1038/nrc745 PMID: 11990853
14. Nomura H, Fujimoto N, Seiki M, Mai M, Okada Y. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. International journal of cancer Journal international du cancer. 1996; 69(1):9-16. Epub 1996/02/20. doi: 10.1002/ (SICI)1097-0215(19960220)69:1<9::AID-IJC3>3.0.CO;2-8 PMID: 8600068
15. Shima I, Sasaguri Y, Kusukawa J, Yamana H, Fujita H, Kakegawa T, et al. Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study. Cancer. 1992; 70(12):2747-53. Epub 1992/12/15. PMID: 1451050
16. Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer. 1998; 83(6):1153-62. Epub 1998/09/18. PMID: 9740080
17. Still K, Robson CN, Autzen P, Robinson MC, Hamdy FC. Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. The Prostate. 2000; 42(1):18-25. Epub 1999/12/01. PMID: 10579795
18. Leinonen T, Pirinen R, Bohm J, Johansson R, Kosma VM. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. Histology and histopathology. 2008; 23(6):693-700. Epub 2008/03/28. PMID: 18366007
19. Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M, Kagawa S. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer. 1998; 82(7):1359-66. Epub 1998/04/07. PMID: 9529029
20. Westerlund A, Apaja-Sarkkinen M, Hoyhtya M, Puistola U, Turpeenniemi-Hujanen T. Gelatinase Aimmunoreactive protein in ovarian lesions-prognostic value in epithelial ovarian cancer. Gynecologic oncology. 1999; 75(1):91-8. Epub 1999/09/30. doi: 10.1006/gyno.1999.5533 PMID: 10502432
21. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980; 284(5751):67-8. Epub 1980/ 03/06. PMID: 6243750
22. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nature reviews Neuroscience. 2001; 2(7):502-11. Epub 2001/07/04. doi: 10.1038/ 35081571 PMID: 11433375
23. Jaalinoja J, Herva R, Korpela M, Hoyhtya M, Turpeenniemi-Hujanen T. Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms. Journal of neuro-oncology. 2000; 46(1):81-90. Epub 2000/07/15. PMID: 10896208
24. Yano H, Hara A, Murase S, Hayashi K, Ando H, Shinoda J, et al. Expression of hepatocyte growth factor and matrix metalloproteinase-2 in human glioma. Brain tumor pathology. 2001; 18(1):7-12. Epub 2001/ 08/24. PMID: 11517976
25. Wang M, Wang T, Liu S, Yoshida D, Teramoto A. The expression of matrix metalloproteinase-2 and-9 in human gliomas of different pathological grades. Brain tumor pathology. 2003; 20(2):65-72. Epub 2004/02/06. PMID: 14756443
26. Nakada M, Nakamura H, Ikeda E, Fujimoto N, Yamashita J, Sato H, et al. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. The American journal of pathology. 1999; 154(2):417-28. Epub 1999/02/23. doi: 10.1016/S0002-9440(10)65288-1 PMID: 10027400
27. Dahlrot RH, Hansen S, Herrstedt J, Schroder HD, Hjelmborg J, Kristensen BW. Prognostic value of Musashi-1 in gliomas. Journal of neuro-oncology. 2013; 115(3):453-61. Epub 2013/09/24. doi: 10. 1007/s11060-013-1246-8 PMID: 24057325
28. Hermansen SK, Dahlrot RH, Nielsen BS, Hansen S, Kristensen BW. MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas. Journal of neuro-oncology. 2013; 111 (1):71-81. Epub 2012/10/30. doi: 10.1007/s11060-012-0992-3 PMID: 23104517
29. Lathia JD, Li M, Sinyuk M, Alvarado AG, Flavahan WA, Stoltz K, et al. High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. Cell reports. 2014; 6(1):117-29. Epub 2014/01/01. doi: 10.1016/j.celrep.2013.11.043 PMID: 24373972
30. Petterson SA, Dahlrot RH, Hermansen SK, S KAM, Gundesen MT, Wohlleben H, et al. High levels of c-Met is associated with poor prognosis in glioblastoma. Journal of neuro-oncology. 2015; 122(3):517-27. Epub 2015/03/25. doi: 10.1007/s11060-015-1723-3 PMID: 25800004
31. Music D, Dahlrot RH, Hermansen SK, Hjelmborg J, de Stricker K, Hansen S, et al. Expression and prognostic value of the WEE1 kinase in gliomas. Journal of neuro-oncology. 2016. Epub 2016/01/08.
32. Dahlrot RH, Sorensen MD, Rosager AM, Hellwege S, Bangso JA, Rosenberg T, et al. Novel approaches for quantifying protein biomarkers in gliomas: benefits and pitfalls. CNS oncology. 2014; 3 (4):287-98. Epub 2014/10/07. doi: 10.2217/cns.14.30 PMID: 25286040
33. Jensen SS, Aaberg-Jessen C, Christensen KG, Kristensen B. Expression of the lysosomal-associated membrane protein-1 (LAMP-1) in astrocytomas. International journal of clinical and experimental pathology. 2013; 6(7):1294-305. Epub 2013/07/05. PMID: 23826410
34. Christensen K, Schroder HD, Kristensen BW. CD133 identifies perivascular niches in grade II-IV astrocytomas. Journal of neuro-oncology. 2008; 90(2):157-70. Epub 2008/07/10. doi: 10.1007/s11060-008-9648-8 PMID: 18612800
35. Silverman JF, Jones FD, Unverferth M, Berns L. Cytopathology of neoplasms of the central nervous system in specimens obtained by the Cavitron Ultrasonic Surgical Aspirator. Acta cytologica. 1989; 33 (5):576-82. Epub 1989/09/01. PMID: 2476903
36. Shi SR, Liu C, Pootrakul L, Tang L, Young A, Chen R, et al. Evaluation of the value of frozen tissue section used as "gold standard" for immunohistochemistry. American journal of clinical pathology. 2008; 129(3):358-66. Epub 2008/02/21. doi: 10.1309/7CXUYXT23E5AL8KQ PMID: 18285257
37. Dahlrot RH, Kristensen BW, Hjelmborg J, Herrstedt J, Hansen S. A population-based study of lowgrade gliomas and mutated isocitrate dehydrogenase 1 (IDH1). Journal of neuro-oncology. 2013; 114(3):309-17. Epub 2013/07/03. doi: 10.1007/s11060-013-1186-3 PMID: 23817809
38. Dahlrot RH, Kristensen BW, Hjelmborg J, Herrstedt J, Hansen S. A population-based study of highgrade gliomas and mutated isocitrate dehydrogenase 1. International journal of clinical and experimental pathology. 2013; 6(1):31-40. Epub 2012/12/14. PMID: 23236540
39. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016; 164(3):550-63. Epub 2016/01/30. doi: 10.1016/j.cell.2015.12.028 PMID: 26824661
40. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061-8. Epub 2008/09/06. doi: 10.1038/ nature07385 PMID: 18772890
41. Jensen SS, Aaberg-Jessen C, Andersen C, Schroder HD, Kristensen BW. Glioma spheroids obtained via ultrasonic aspiration are viable and express stem cell markers: a new tissue resource for glioma research. Neurosurgery. 2013; 73(5):868-86; discussion 86. Epub 2013/07/28. doi: 10.1227/NEU. 0000000000000118 PMID: 23887192
42. Jensen SS, Meyer M, Petterson SA, Halle B, Rosager AM, Aaberg-Jessen C, et al. Establishment and Characterization of a Tumor Stem Cell-Based Glioblastoma Invasion Model. PloS one. 2016; 11(7): e0159746. Epub 2016/07/28. doi: 10.1371/journal.pone.0159746 PMID: 27454178
43. Kolenda J, Jensen SS, Aaberg-Jessen C, Christensen K, Andersen C, Brunner N, et al. Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. Journal of neuro-oncology. 2011; 103(1):43-58. Epub 2010/09/14. doi: 10.1007/s11060-010-0357-8 PMID: 20835751
44. Munthe S, Sørensen MD, Thomassen M, Burton M, Kruse TA, Lathia JD, et al. Migrating glioma cells express stem cell markers and give rise to new tumors upon xenografting. Journal of neuro-oncology. 2016; 130(1):53-62. doi: 10.1007/s11060-016-2221-y PMID: 27510953
45. Gavrielides MA, Gallas BD, Lenz P, Badano A, Hewitt SM. Observer variability in the interpretation of HER2/neu immunohistochemical expression with unaided and computer-aided digital microscopy. Archives of pathology & laboratory medicine. 2011; 135(2):233-42. Epub 2011/02/03.
46. Laurinaviciene A, Dasevicius D, Ostapenko V, Jarmalaite S, Lazutka J, Laurinavicius A. Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays. Diagnostic pathology. 2011; 6:87. Epub 2011/09/29. doi: 10.1186/1746-1596-6-87 PMID: 21943197
47. Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. International journal of cancer Journal international du cancer. 2005; 115(6):849-60. Epub 2005/02/25. doi: 10.1002/ ijc.20945 PMID: 15729716
48. Thorns V, Walter GF, Thorns C. Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer research. 2003; 23(5A):3937-44. Epub 2003/12/12. PMID: 14666700
49. Hua Y, Zhang W, Xie Z, Xu N, Lu Y. MMP-2 Is Mainly Expressed in Arterioles and Contributes to Cerebral Vascular Remodeling Associated with TGF-beta1 Signaling. Journal of molecular neuroscience: MN. 2015. Epub 2015/11/23.
50. Gu J, Zhang C, Chen R, Pan J, Wang Y, Ming M, et al. Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas. European journal of pediatrics. 2009; 168(6):705-10. Epub 2008/09/17. doi: 10.1007/s00431-008-0828-5 PMID: 18795327
51. Kunishio K, Okada M, Matsumoto Y, Nagao S. Matrix metalloproteinase-2 and-9 expression in astrocytic tumors. Brain tumor pathology. 2003; 20(2):39-45. Epub 2004/02/06. PMID: 14756439
52. Xia L, Wu B, Fu Z, Feng F, Qiao E, Li Q, et al. Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies. Oncotarget. 2015; 6(19):17354-65. Epub 2015/07/30. doi: 10.18632/ oncotarget.4008 PMID: 26220714
53. da Silva R, Uno M, Marie SK, Oba-Shinjo SM. LOX expression and functional analysis in astrocytomas and impact of IDH1 mutation. PloS one. 2015; 10(3):e0119781. Epub 2015/03/20. doi: 10.1371/journal. pone.0119781 PMID: 25790191
54. Wang JB, Dong DF, Gao K, Wang MD. Mechanisms underlying the biological changes induced by isocitrate dehydrogenase-1 mutation in glioma cells. Oncology letters. 2014; 7(3):651-7. Epub 2014/02/13. doi: 10.3892/ol.2014.1806 PMID: 24520288
55. Kessler J, Guttler A, Wichmann H, Rot S, Kappler M, Bache M, et al. IDH1(R132H) mutation causes a less aggressive phenotype and radiosensitizes human malignant glioma cells independent of the oxygenation status. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2015; 116(3):381-7. Epub 2015/09/04.
56. Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, Bosch KS, et al. The prognostic IDH1 (R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta neuropathologica. 2010; 119(4):487-94. Epub 2010/02/04. doi: 10.1007/s00401-010-0645-6 PMID: 20127344
57. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer cell. 2006; 9(3):157-73. Epub 2006/03/15. doi: 10.1016/j.ccr.2006.02.019 PMID: 16530701
58. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell. 2010; 17(1):98-110. Epub 2010/02/05. doi: 10.1016/j.ccr.2009.12.020 PMID: 20129251
59. Karsy M, Gelbman M, Shah P, Balumbu O, Moy F, Arslan E. Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features. Folia neuropathologica / Association of Polish Neuropathologists and Medical Research Centre, Polish Academy of Sciences. 2012; 50 (4):301-21. Epub 2013/01/16.
60. Coniglio SJ, Eugenin E, Dobrenis K, Stanley ER, West BL, Symons MH, et al. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Molecular medicine (Cambridge, Mass). 2012; 18:519-27. Epub 2012/02/02.
61. Piao Y, Liang J, Holmes L, Zurita AJ, Henry V, Heymach JV, et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro-oncology. 2012; 14(11):1379-92. Epub 2012/09/12. doi: 10.1093/neuonc/nos158 PMID: 22965162
62. Bhat KP, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer cell. 2013; 24(3):331-46. Epub 2013/09/03. doi: 10.1016/j.ccr.2013.08.001 PMID: 23993863
63. Habberstad AH, Lind-Landstrom T, Sundstrom S, Torp SH. Primary human glioblastomas - prognostic value of clinical and histopathological parameters. Clinical neuropathology. 2012; 31(5):361-8. Epub 2012/09/04. PMID: 22939176
64. Nagaishi M, Paulus W, Brokinkel B, Vital A, Tanaka Y, Nakazato Y, et al. Transcriptional factors for epithelial-mesenchymal transition are associated with mesenchymal differentiation in gliosarcoma. Brain pathology (Zurich, Switzerland). 2012; 22(5):670-6. Epub 2012/02/01.
65. Rutledge WC, Kong J, Gao J, Gutman DA, Cooper LA, Appin C, et al. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19 (18):4951-60. Epub 2013/07/19.
66. Cohen-Inbar O, Zaaroor M. Immunological Aspects of Malignant Gliomas. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques. 2016; 43(4):494-502. Epub 2016/ 06/22. doi: 10.1017/cjn.2016.34 PMID: 27324313
67. Paldor I, Drummond KJ, Kaye AH. IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study. Journal of Clinical Neuroscience. 2016; 34:117-20. http://dx.doi.org/10.1016/j.jocn.2016.05.016. PMID: 27522495
68. Wirsching H-G, Galanis E, Weller M. Chapter 23 - Glioblastoma. In: Mitchel SB, Michael W, editors. Handbook of Clinical Neurology. Volume 134: Elsevier; 2016. p. 381-97.
69. Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-oncology. 2005; 7(4):436-51. Epub 2005/10/11. doi: 10.1215/S1152851705000050 PMID: 16212809
70. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer cell. 2003; 3(4):347-61. Epub 2003/05/03. PMID: 12726861
71. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(17):2817-23. Epub 2010/05/12.
72. Tabouret E, Boudouresque F, Barrie M, Matta M, Boucard C, Loundou A, et al. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro-oncology. 2014; 16(3):392-9. Epub 2013/12/12. doi: 10.1093/ neuonc/not226 PMID: 24327581